Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised

Revenue Details Revvity reports under two operating segments — Life Sciences and Diagnostics. Adjusted operating income amounted to $112.4 million, down 12% from the prior-year quarter. Margin Analysis The company exited the second quarter of 2024 with cash and cash equivalents of $1.95 billion compared with $1.70 billion in the prior-quarter end. Price Performance Some better-ranked stocks in the broader medical space that have announced quarterly results are Boston Scientific Corporation (BSX) , Hologic ( ...